Details

Autor(en) / Beteiligte

• Mehta, Rupa
• Nagarkar, Nitin M.
• Jindal, Atul
• Rao, Karthik Nagaraja
• Nidhin, S. B.
• Arora, Ripu Daman
• Sharma, Anil
• Wankhede, Archana
• Satpute, Satish
• Chakravarty, Sharmistha
• Agrawal, N. K.
• Pranita
• Kannauje, Pankaj
• Behera, Ajoy
• Thangaraju, Pugazhenthan

Titel

Multidisciplinary Management of COVID-Associated Mucormycosis Syndemic in India

Ist Teil von

• Indian journal of surgery, 2022-10, Vol.84 (5), p.934-942

Ort / Verlag

New Delhi: Springer India

Erscheinungsjahr

2022

Link zum Volltext

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• The study aimed to determine clinical presentation, contributing factors, medical and surgical management, and outcome of patients with coronavirus disease 2019 (COVID-19)-associated mucormycosis (CAM). A cross-sectional, single-center study was conducted on patients receiving multidisciplinary treatment for mucormycosis following the second wave of COVID-19 pandemic from April to June 2021 in India. Clinicoepidemiological factors were analyzed, 30-day overall survival and disease-specific survival were determined, and t -test was used to determine the statistical significance. A total of 215 patients were included in the study, the cases were stratified into sino-nasal 95 (44.2%), sino-naso-orbital 32 (14.9%), sino-naso-palatal 55 (25.6%), sino-naso-cerebral 12 (5.6%), sino-naso-orbito-cerebral 16 (7.4%), and sino-naso-orbito-palato-cerebral 5 (2.3%) based on their presentation. A multidisciplinary team treated patients by surgical wound debridement and medical therapy with broad-spectrum antibiotics and amphotericin B. Across all disease stages, cumulative 30-day disease-specific survival is 94% ( p  < 0.001, intergroup comparison, Breslow (generalized Wilcoxon) CI 95%) and overall 30-day survival is 87.9% ( p  < 0.001, intergroup comparison, Breslow (generalized Wilcoxon) CI 95%) (censored). Early identification, triaging, and proper multidisciplinary team management with systemic antifungals, surgical debridement, and control of comorbidities lead to desirable outcomes in COVID-associated mucormycosis. The patients with intracranial involvement have a higher chance of mortality compared to the other group.